CDKN2B是抑癌基因，编码蛋白（cyclin-dependent kinase (CDK) inhibitor 2B）也称为p15或INK4B，是一种细胞周期蛋白依赖性激酶（CDK）抑制剂，有助于调节细胞周期进程。p15通过阻止CDK4和CDK6与细胞周期蛋白的结合来抑制CDK4和CDK6。 这激活视网膜母细胞瘤（Rb）蛋白家族，其阻断G1至S期转变并可导致细胞周期停滞或静止。 CDKN2B表达也已显示调节TGFβ介导的细胞周期停滞。CDKN2B胚系突变可导致肾细胞癌的易感性。小鼠模型中CDKN2B的缺失可导致肿瘤进展；CDKN2B经常在多种肿瘤中被删除，高甲基化或突变，大多数情况是通过突变或者缺失而失活。

CDKN2B (cyclin-dependent kinase (CDK) inhibitor 2B), also known as p15 or INK4B, is a cyclin-dependent kinase (CDK) inhibitor that helps regulate cell cycle progression. p15 inhibits CDK4 and CDK6 by preventing their binding to cyclins. This activates the retinoblastoma (Rb) family of proteins, which blocks the G1 to S-phase transition and can result in cell cycle arrest or quiescence. CDKN2B expression has also been shown to regulate TGFβ-mediated cell cycle arrest. Germline mutations in CDKN2B can result in a predisposition to renal cell carcinoma. Deletion of CDKN2B in murine models can result in tumor progression, consistent with its role as a tumor suppressor and it is frequently deleted, hypermethylated, or mutated in a variety of tumors.

GeneCards OncoKB My Cancer Genome